PharmaShots | Incisive News in 3 Shots

Subscribe Now

STADA

STADA and Alvotech Introduces Uzpruvo (Biosimilar, Stelara) Across the EU

STADA and Alvotech Introduces Uzpruvo (Biosimilar, Stelara) Across the EU

July 22, 2024

STADA and Alvotech’s Uzpruvo (Biosimilar, Stelara) Obtains EC’s Approval for Immune-Mediated Diseases

STADA and Alvotech’s Uzpruvo (Biosimilar, Stelara) Obtains EC’s Approval for Immune-Mediated Diseases

January 10, 2024

STADA and Xbrane Report P-III Study Results of Ximluci (biosimilar, ranibizumab) for the Treatment of Neovascular Age-Related Macular Degeneration

STADA and Xbrane Report P-III Study Results of Ximluci (biosimilar, ranibizumab) for the Treatment of Neovascular Age-Related Macu...

June 23, 2023

STADA and Xbrane Launch Ximluci (biosimilar, ranibizumab) for Ophthalmic Conditions in the EU

STADA and Xbrane Launch Ximluci (biosimilar, ranibizumab) for Ophthalmic Conditions in the EU

April 3, 2023

STADA and Xbrane Receives the MHRA’s Approval for Ximluci (biosimilar, ranibizumab) to Treat Retinal Diseases

STADA and Xbrane Receives the MHRA’s Approval for Ximluci (biosimilar, ranibizumab) to Treat Retinal Diseases

January 6, 2023

STADA and Xbrane Receive EC’s Marketing Authorization of Ximluci (biosimilar, ranibizumab) for Retinal Disorders

STADA and Xbrane Receive EC’s Marketing Authorization of Ximluci (biosimilar, ranibizumab) for Retinal Disorders

November 11, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us